HUMIRA

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

New Delhi, February 22, 2019: (JCN Newswire) – AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they…

6 years ago

AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA

Tokyo, June 24, 2018: AbbVie GK, Eisai Co., Ltd. and Eisai’s subsidiary for gastrointestinal diseases EA Pharma Co., Ltd.announced that the…

7 years ago